HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence

Journal for ImmunoTherapy of Cancer · Published 2026-06-01 · DOI 10.1136/jitc-2025-014327

Free full text

Authors (10)

Xiao Zhang, Liu Huang, Jiayao Li, Yixin Cai, Wei Chen, Yijiu Ren, Xianglin Yuan, Wei Sun, Shuguo Sun, Qian Chu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhang, X., Huang, L., Li, J., et al. (2026). HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014327

Related articles

• TGF-β1 drives neutrophil extracellular traps formation to promote CD8 + T cell exhaustion via the ERK-c-Fos-JunB axis, mediating gastric cancer immunotherapy resistance · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphoma · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Systemic immune profiling in hepatocellular carcinoma: navigating etiological heterogeneity and selection bias · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• In situ generation of proinflammatory CAR macrophages via mRNA-TLR agonist co-delivery for triple-negative breast cancer immunotherapy · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma · Journal for ImmunoTherapy of Cancer · 2026 · Same journal